Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

• Post author:andrewkaretas
• Post published:February 12, 2025
• Post category:CD19/Scientific Publications

Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

• Post author:andrewkaretas
• Post published:December 9, 2024
• Post category:CD19/Scientific Publications

Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

• Post author:andrewkaretas
• Post published:November 18, 2024
• Post category:Dual/Scientific Publications

Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

• Post author:andrewkaretas
• Post published:November 7, 2024
• Post category:CD70/Scientific Publications

Continue ReadingALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

New Frontiers for CAR-T

• Post author:andrewkaretas
• Post published:November 1, 2024
• Post category:Perspectives

Continue ReadingNew Frontiers for CAR-T

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

• Post author:andrewkaretas
• Post published:July 15, 2024
• Post category:Uncategorized

Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

FT US Pharma and Biotech Summit

• Post author:andrewkaretas
• Post published:June 12, 2024
• Post category:Perspectives/Uncategorized

Continue ReadingFT US Pharma and Biotech Summit

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

• Post author:andrewkaretas
• Post published:December 11, 2023
• Post category:CD19/Scientific Publications

*In collaboration with The University of Texas MD Anderson Cancer Center.

Continue ReadingCellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

• Post author:andrewkaretas
• Post published:December 9, 2023
• Post category:ALLO-647/Scientific Publications

Continue ReadingALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Unlocking the Fourth Great Wave in Cancer Treatment

• Post author:andrewkaretas
• Post published:November 8, 2023
• Post category:Perspectives

Continue ReadingUnlocking the Fourth Great Wave in Cancer Treatment